• MMRF Launches Fund to Invest in Innovative Firms for Multiple Myeloma Research
  • Cellectis Plans Clinical Trial to Test Donor-derived CAR T-cell Therapy, Possible Multiple Myeloma Treatment
  • Trial to Evaluate Daratumumab/Revlimid as Maintenance for Some Multiple Myeloma Patients
  • MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients
  • Janssen Seeks Approval of Darzalex Add-on for Newly Diagnosed Multiple Myeloma Patients in Japan
  • Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show
  • GSK Compound Showing Durable Response Rates in Advanced Multiple Myeloma, New Phase 1 Trial Data Find
  • OncoTracker Acquires Global Rights to Diagnostic Test, Possible Combo Therapy for Multiple Myeloma
  • European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients
  • FDA Delays Decision on Selinexor’s Approval for Heavily Treated Multiple Myeloma
  • FDA Application Submitted for Darzalex Combo Therapy to Treat Certain Multiple Myeloma Patients
  • FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials